GSK plc (GSK.L)
| Previous close | 1,651.50 |
| Open | 1,653.00 |
| Bid | 1,665.00 x 0 |
| Ask | 1,665.50 x 0 |
| Day's range | 1,653.00 - 1,668.00 |
| 52-week range | 1,359.60 - 1,823.50 |
| Volume | |
| Avg. volume | 7,716,035 |
| Market cap | 67.588B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 14.66 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.60 (3.62%) |
| Ex-dividend date | 15 Aug 2024 |
| 1y target est | N/A |
- GlobeNewswire
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and in
- Business Wire
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA, August 01, 2024--Expanded approval of Jemperli (dostarlimab-gxly) plus chemo in endometrial cancer as first & only IO-based treatment to show overall survival benefit
- Business Wire
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
PHILADELPHIA, July 11, 2024--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA).
